Company news

Palvella Therapeutics, Inc. (NASDAQ:PVLA) news

Palvella Therapeutics, Inc. news releases on 6ix. Latest, Sep 28, 2026: U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin…

Palvella Therapeutics, Inc. (NASDAQ:PVLA) news

Press releases & updates

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations

Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Ligand to Participate in May Investor Conferences

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations

Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting

Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin

Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Palvella Therapeutics Announces Pricing of Upsized Public Offering

Palvella Therapeutics Announces Proposed Public Offering

Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-app...

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update